Loading
A phase 2 trial of Livmoniplimab, Budigalimab, Docetaxel and Gemcitabine in bladder & urothelial cancer, run by AbbVie, active and no longer recruiting.
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) is a phase 2 interventional study registered as NCT06632951 by AbbVie, with 150 participants enrolled, started 2025-01-20 and due to reach its primary completion in 2027-03. Interventions recorded: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel and Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Muscle-invasive and advanced bladder cancer, Docetaxel, Bladder & urothelial cancer and the tag pipeline.
Shares Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Budigalimab, AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/